Download
clinical trials n.
Skip this Video
Loading SlideShow in 5 Seconds..
Clinical Trials PowerPoint Presentation
Download Presentation
Clinical Trials

Clinical Trials

349 Vues Download Presentation
Télécharger la présentation

Clinical Trials

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Clinical Trials The Way We Make Progress Against Disease

  2. What Are Clinical Trials? • Research studies involving people • Try to answer scientific questions and find better ways to prevent, diagnose, or treat disease

  3. Why Is Participation in Clinical Trials Important? • The more people take part, the faster we can: - Answer critical research questions - Find better treatments and ways to prevent disease

  4. Do Many People Take Part in Clinical Trials? • Few people participate

  5. What Are Different Types of Clinical Trials? • Prevention • Treatment • Tumor or normal tissue studies • Early detection/screening • Diagnostic • Quality of life/supportive care

  6. Prevention Trials • Evaluate the effectiveness of ways to reduce the risk of a particular disease • Enroll healthy people at high risk for developing that disease

  7. Treatment Trials • What new treatments can help people with a particular disease? • What is the most effective treatment for people with that disease?

  8. Clinical Trial Phases Phase 1 trials • How does the agent affect the human body? • What dosage is safe? • What is the best dose to use for phase 2 trials?

  9. Clinical Trial Phases Phase 2 trials • Does the agent or intervention have an effect on a specific disease? • The majority of trials in neuroendocrine cancers are phase II trials

  10. Clinical Trial Phases Phase 3 trials • Is the new agent or intervention (or new use of a treatment) better than the standard? • Require large numbers of patients to answer questions

  11. Randomized Phase III Trials Participants have an equal chance to be assigned to one of two or more groups: • One gets the most widely accepted treatment (standard treatment) • The other gets the new treatment being tested, which researchers hope and have reason to believe will be better than the standard treatment

  12. Randomization

  13. Why is Randomization Important? • So all groups are as alike as possible (Even when unintended, selection bias is a major limitation to non-randomized studies.) • Provides the best way to prove the effectiveness of a new agent or intervention

  14. Clinical Trial Protocol • A recipe or blueprint • Strict scientific guidelines: --Purpose of study --How many people will participate --Who is eligible to participate --How the study will be carried out --What information will be gathered about participants --Endpoints

  15. Benefits of Participation Possible benefits: • Patients will receive, at a minimum, the best standard treatment (if one exists) • If the new treatment or intervention is proven to work, patients may be among the first to benefit • Patients have a chance to help others and improve patient care

  16. Risks of Participation Possible risks: • New treatments or interventions under study are not always better than, or even as good as, standard care • Even if a new treatment has benefits, it may not work for every patient

  17. Patient Protection • Federal regulations ensure that people are told about the benefits, risks, and purpose of research before they agree to participate

  18. How Are Patients’ Rights Protected? • Informed consent • Scientific review • Institutional review boards (IRBs) • Data safety and monitoring boards (DSMBs)

  19. How Are Patients’ Rights Protected? Informed Consent: • Purpose • Procedures • Potential risks and benefits • Individual rights

  20. How Are Patients’ Rights Protected? • Scientific review (NCI designated Cancer Centers require this for all trials) • Institutional review boards (IRBs) are required by federal law for trials that are: --Federally funded --Subject to FDA regulation

  21. How Are Patients’ Rights Protected? Data and safety monitoring boards: • Ensure that risks are minimized • Ensure data integrity • Stop a trial if safety concerns arise or objectives have been met

  22. Why Do So Few People Participate in Clinical Trials? Sometimes patients: • Don’t know about clinical trials • Don’t have access to clinical trials • May be afraid or suspicious of research • Can’t afford to participate • May not want to go against health care provider’s wishes

  23. Why Do So Few People Participate in Clinical Trials? Health care providers might: • Lack awareness of appropriate clinical trials • Be unwilling to “lose control” of a person’s care • Believe that standard therapy is best • Be concerned that clinical trials add administrative burdens

  24. DFHCC Clinical Trials in Neuroendocrine Tumors • Therapeutic: • A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues. • Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC#704865) in Advanced, Poor Prognosis Carcinoid • Patients Non-Therapeutic: • Sample Collection in Patients with Neuroendocrine • Protein Expression in Carcinoid Tumors

  25. DFHCC Clinical Trials in Neuroendocrine Tumors • Therapeutic: (Pending) • Ph II AMG479 in Carcinoid and Panc Neuroendocrine • Octreotide Implant in Carcinoid • LX 1006 in Carcinoid pts. Refractory to Octreotide

  26. Your health care provider National Library of Medicine www.ClinicalTrials.gov Where to Find Additional Clinical Trial Information :

  27. Neuroendocrine Cancers • The important role of a multimodality approach to the disease from time of diagnosis but continuing throughout the course of the patient’s care, including: • Surgeons for resections of primary lesions and where appropriate, metastatic disease • Interventional and/or Vascular radiologists for directed therapies (such as RFA or chemoembolization) especially for liver lesions • Medical oncologists for systemic therapy, including LAR octreotide treatment as well as various chemotherapeutic agents as appropriate • Radiation oncologists for treatment of appropriate disease such as painful bony lesions.

  28. Neuroendocrine Tumors (conclusion continued) • The variable natural history of these tumors. • Some individuals, such as this patient, have a relatively indolent history, doing quite well despite metastatic disease • Others have a more aggressive course requiring ongoing chemotherapy or chemoembolization to control their disease and symptoms

  29. Neuroendocrine Tumors (conclusion continued) • Thus, this is a disease where it is very important that each patient be evaluated carefully by the different disciplines and has disease tailored appropriately.